New Challenges Facing Systemic Therapies of Advanced HCC in the Era of Different First-Line Immunotherapy-Based Combinations.

Cancers (Basel) · 2022 · PMC9739025 · PMID 36497349

Europe PMC DOI

hedged sentence

0.0750

closest p · 1.5× alpha

0.0750

boldest claim

The sentences

a positive trendp = 0.075so close (0.05 < p ≤ 0.1)

In the Checkmate-459, nivolumab failed to demonstrate superiority, despite a positive trend in OS (median OS of 16.4 vs. 14.7 months, HR = 0.85 (95%CI: 13.9–18.4, p = 0.075 for superiority), a better toxicity profile, and improved QoL.

also in 11,005 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.